OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology

2022 is set to be a milestone year for OriCell who has been focusing on the field of cancer immunotherapy for more than seven years and is fully c...

Related Keywords

China ,Qiming ,Sichuan ,Australia ,Shanghai ,United States ,Chinese ,Australian ,American ,Weidong Cui ,Helen Yang ,Australian Therapeutic Goods Administration ,Technology Officer ,American Society Of Clinical Oncology ,Prnewswire Oricell Therapeutics Shanghai Co Ltd ,National Medical Products Administration ,Drug Administration ,Cell Therapeutics ,Qiming Venture Partners ,Quan Capital ,Investigational New Drug ,Clinical Oncology ,Only Grade ,Drug Evaluation ,Clinical Trials Notification ,Chief Technology ,Fosun Kite ,Oricell Therapeutics ,